Search research articles
Contact Us
Filters
Showing results (21-30 of 91) with videos related to
Page
of 10
Sort By:
Clinical Pharmacology in Drug Development
|
July 12, 2022
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma
Andres Forero-Torres, Jason Claud Chandler, Swaminathan P Iyer, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
March 2, 2010
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)
Andres Forero-Torres, Jatin Shah, Tina Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499
Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Blood
|
April 27, 2018
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Tycel J Phillips, Andres Forero-Torres, Taimur Sher, et al.
Leukemia & Lymphoma
|
February 5, 2015
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
Luis Fayad, Stephen M Ansell, Ranjana Advani, et al.
Plos One
|
September 9, 2017
Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans
Madison R Chandler, Kimberly S Keene, Johanna M Tuomela, et al.
Leukemia & Lymphoma
|
July 11, 2012
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
Andres Forero-Torres, Nancy Bartlett, Anne Beaven, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 14, 2018
O-GlcNAcylation of GLI transcription factors in hyperglycemic conditions augments Hedgehog activity
Shamik Das, Sarah K Bailey, Brandon J Metge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2011
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies
Michelle A Fanale, Andres Forero-Torres, Joseph D Rosenblatt, et al.
British Journal of Haematology
|
May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres, John P Leonard, Anas Younes, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 91) with videos related to
Sort By:
Page
of 10
Clinical Pharmacology in Drug Development
|
July 12, 2022
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma
Andres Forero-Torres, Jason Claud Chandler, Swaminathan P Iyer, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
March 2, 2010
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)
Andres Forero-Torres, Jatin Shah, Tina Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499
Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Blood
|
April 27, 2018
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Tycel J Phillips, Andres Forero-Torres, Taimur Sher, et al.
Leukemia & Lymphoma
|
February 5, 2015
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
Luis Fayad, Stephen M Ansell, Ranjana Advani, et al.
Plos One
|
September 9, 2017
Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans
Madison R Chandler, Kimberly S Keene, Johanna M Tuomela, et al.
Leukemia & Lymphoma
|
July 11, 2012
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
Andres Forero-Torres, Nancy Bartlett, Anne Beaven, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 14, 2018
O-GlcNAcylation of GLI transcription factors in hyperglycemic conditions augments Hedgehog activity
Shamik Das, Sarah K Bailey, Brandon J Metge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2011
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies
Michelle A Fanale, Andres Forero-Torres, Joseph D Rosenblatt, et al.
British Journal of Haematology
|
May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres, John P Leonard, Anas Younes, et al.
Page
of 10